HoloMD Appoints New CEO to Scale Psychiatry Platform
The Rockville-based health-tech firm is looking to attract capital and expand its clinical model to millions of new patients.
Updated on Oct. 27, 2026 in People
Live Poll
Do you trust AI-powered mental health tools to improve long-term patient care?
Rockville-based HoloMD has appointed former Eliza co-founder Irene Lang as CEO and co-founder to lead the company as it expands its AI-driven mental health platform. Founder Bruce Alan Kehr will transition to the role of Chief Medical Innovation Officer as the firm looks to scale its clinical operations.
Why it matters
HoloMD is shifting focus toward building products and attracting capital to establish a category of continuous precision psychiatry. Bringing in a leader with experience in rapid startup acquisition and model development signals a move from experimental tech to commercial scaling.
A 180-day pilot of the Dr. Holo platform at Banyan Treatment Centers yielded 83% patient retention across 138 enrollees. The system flagged 43 human-reviewed escalations during the trial, 19 of which were relapse-related alerts.
The players
Irene Lang
The new CEO and co-founder of HoloMD who previously co-founded Eliza before its acquisition by Spring Health.
Bruce Alan Kehr
The founder of HoloMD who transitions to Chief Medical Innovation Officer and has over 40 years of experience in precision psychiatry.
HoloMD
A Rockville-based health technology company that operates an AI-driven platform for patient supervision and clinical risk detection.
Banyan Treatment Centers
A treatment provider that serves as a pilot site for clinical testing of health technology platforms.
The details
HoloMD utilizes machine-learning models to provide clinical decision support and human-reviewed risk detection. The platform integrates clinical philosophy into reimbursement-enabled workflows to bridge the gap between AI oversight and provider-led patient care. By pairing founder Dr. Bruce Alan Kehr’s clinical background with Lang’s expertise in decision-support systems, the company intends to standardize its psychiatry model for a broader patient population.
Timeline
October 27, 2026: Irene Lang officially joins HoloMD as CEO and co-founder.
2026: Potomac Psychiatry, an affiliate, receives global practice of the year honors.
Market Landscape
HoloMD’s transition follows its 2026 Mental Health Tech Innovators of the Year recognition, which marks its shift from experimental development to wider market adoption. The move mirrors a broader trend in health-tech where companies leverage proven patient retention metrics to secure capital for scaling.
Operators in the mental health space should monitor HoloMD’s ability to turn pilot data into sustained reimbursement-enabled workflows. If successful, the platform's focus on relapse-related alerts could set a new benchmark for clinical risk-detection standards.
The takeaway
Management transitions often signal a shift in corporate priorities from technological validation to aggressive commercial growth. Owners should look to benchmark their own clinical retention metrics against HoloMD’s reported 83% retention rate to gauge the effectiveness of current decision-support tools.
Further reading
For additional context on leadership shifts in the local health-tech sector, read the latest People updates.
More information
View the full press release on the corporate news portal.
Source note: This article includes information reported by VentureBeat.
Live Poll
Do you trust AI-powered mental health tools to improve long-term patient care?
